<DOC>
	<DOCNO>NCT01066858</DOCNO>
	<brief_summary>The purpose study look effect tenofovir disoproxil fumarate ( anti-HIV medication ) bone health kidney woman HIV pregnancy breastfeeding . The study also look change overall health , bone health kidney work infant woman .</brief_summary>
	<brief_title>Study Effects Tenofovir Bone Health Kidneys During Pregnancy Breastfeeding</brief_title>
	<detailed_description>A small number adult ( pregnant ) child take anti-HIV medication develop problem kidneys strength bone . These problem may common tenofovir disoproxil fumarate ( TDF ) use . Studies bone kidney effect do pregnant breastfeed woman infant . This substudy large study ( IMPAACT 1077 PROMISE [ Promoting Maternal Infant Survival Everywhere ] ) evaluate safety anti-HIV medication use pregnancy breastfeed . Only participant large study randomly assign receive maternal tenofovir disoproxil fumarate ( TDF ) maternal TDF pregnancy breastfeed enrol substudy . This substudy look two group participant : - An antepartum exposure group look effect TDF pregnancy - A postpartum exposure group look effect TDF breastfeed All mother-infant pair substudy follow 74 week delivery . During time , woman infant medical checkup test . The test include test blood , urine , cord blood , breast milk . Some woman infant special x-ray call dual energy e-ray absorptiometry ( DXA ) scan measure bone strength . The timing tests—at enrollment , delivery , 6 , 10 , 26 , 74 weeks—will vary dependent part substudy woman infant enrol . Those charge substudy try schedule medical visit test time test schedule large IMPAACT 1077 study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Antepartum ( AP ) Part Study ( TDF Exposure During Pregnancy ) Motherinfant pair enrol 1077BA 1077FA At clinical site approve P1084s DXA site Enrolled substudy Week 2 visit 1077BA/1077FA ( within 21 day 1077BA/1077FA study entry ) prior start labor Willing able provide write informed consent participate substudy Postpartum ( PP ) Part Substudy ( TDF Exposure During Breastfeeding ) ( Note : applies new enrollment P1084s , i.e. , enrol P1084s AP component ) Mother infant enrol 1077BP At clinical site approve P1084s DXA site Enrolled substudy within 6 14 day delivery , day enrollment 1077BP Willing able provide write informed consent participate substudy TDF exposure pregnancy [ NOTE : TDF use 12 day begin labor allow ] Enrolled AP part P1084s</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>renal bone toxicity</keyword>
	<keyword>pregnancy</keyword>
	<keyword>breastfeeding</keyword>
	<keyword>mother child transmission</keyword>
</DOC>